Introduction {#s001}
============

D[yschromatosis symmetrica hereditaria]{.smallcaps} (DSH; MIM: No. 127400) is a pigmentary genodermatosis of autosomal dominant inheritance. It is characterized by the presence of intermingled hyperpigmented and hypopigmented macules located primarily on the dorsal aspects of the extremities. Occasionally freckle-like macules located on the face can appear in patients with DSH. DSH is caused by pathogenic mutations in the *ADAR1* gene (Miyamura *et al.*, [@B11]). It is thought to be a rare genodermatosis though the exact frequency of this disease is unknown (Hayashi and Suzuki, [@B3]) since the epidermal symptoms can be easily ignored by patients owing to numerous factors such as skin color and disease severity.

*ADAR1* maps to chromosome 1q21.1--21.2 (Miyamura *et al.*, [@B11]; Zhang *et al.*, [@B22]), spans up to 40 kb, and contains 15 exons (Wang *et al.*, [@B21]). It encodes adenosine deaminase acting on RNA (ADAR), which includes an interferon-inducible long-form protein ADAR1p150 and a constitutively expressed short-form protein ADAR1p110 due to alternative splicing (Patterson and Samuel, [@B12]). ADAR1 has been long recognized as an essential enzyme for normal mammalian development. Recent researches indicate that ADAR1 not only catalyzes the conversion from adenosine to inosine but also participates in gene regulation through editing-independent manners (Song *et al.*, [@B17]). Till now, several possible correlations between ADAR1 and human diseases have been identified, but the pathogenic mechanism of DSH still remains unexplained.

In this study, we aimed to identify novel mutations in the *ADAR1* gene of Chinese patients with DSH. It may provide more information for further investigation on the pathogenic mechanism of DSH and the exact role of *ADAR1* in this disease.

Materials and Methods {#s002}
=====================

Study subjects {#s003}
--------------

This study enrolled 13 patients who were diagnosed with DSH at our department from October 2015 to July 2017. Of these, eight patients claimed that members of their pedigree also had clinical manifestations of DSH. In addition, this study involved 100 healthy individuals who were randomly selected from the medical staff and medical students at our institution, and their friends. General physical examinations and detailed history taking were conducted in all participants to ensure that none of them had any other diseases that would confuse the diagnosis of DSH.

Genetic studies {#s004}
---------------

The study protocol was approved by Ethical Committee of the Second Affiliated Hospital of Xi\'an Jiaotong University. After informed consent, peripheral blood samples were collected from the participants. Primers flanking all the 15 exons and the adjacent introns of *ADAR1* were designed using Primer3.0 (Untergasser *et al.*, [@B18]). Polymerase chain reaction (PCR) assays of the *ADAR1* gene were performed on the extracted genome, as described previously (Li *et al.*, [@B8]). The purified PCR products of each exon and adjacent intron sequences of *ADAR1* were directly sequenced on the ABI3730XL DNA analyzer (Applied Biosystems, CA). Novel mutations were identified through comparing the sequencing outcomes with the previously published articles and the single nucleotide polymorphism database.

Results {#s005}
=======

All the 13 patients in this study are Han nationality from Shaanxi Province, China. They consist of eight male patients and five female patients with age ranging from 7 to 63 years. The median onset time among the patients is 3 years old. Skin lesions consisted of freckle-like macules distributed on the face and intermingled macules distributed mainly on the dorsal aspects of the extremities. Intermingled lesions of hyperpigmented and hypopigmented macules were found on the extensor aspects of knees in one familial patient. All these skin lesions were of irregular shapes and varied sizes. No other symptoms or signs were involved in all the 13 patients.

The detailed personal information, clinical manifestations, onset time of the disease, and demographic information of the enrolled patients are presented in [Table 1](#T1){ref-type="table"} and [Figure 1](#f1){ref-type="fig"}, respectively. Sanger sequencing of PCR products revealed eight novel *ADAR1* mutations and five recurrent mutations ([Fig. 2](#f2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). The novel mutations include two frame-shift mutations (c.1202_1205del, c.2311insA), three missense mutations (c.2749A\>G, c.2894C\>A, and c.3233G\>A), one nonsense mutation (c.2280C\>A), and two splice-site mutations (c.1934 + 3A\>G, c.3019 + 1G\>T).

![Clinical manifestations of enrolled patients with dyschromatosis symmetrica hereditaria: **(a)** clinical manifestations of patient No. 2, intermingled lesions of hyperpigmented and hypopigmented macules on the dorsal aspect of hands; **(b)** clinical manifestations of patient No. 4, freckle-like macules distributed sparsely on the face; **(c)** clinical manifestations of patient No. 13, hyperpigmented and hypopigmented macules on the extensor aspect of knees; **(d)** clinical manifestation of patient No. 5, skin lesions on the hands of a male adult; **(e)** clinical manifestations of patient No. 11, intermingled lesions of hyperpigmented and hypopigmented macules on the dorsal aspect of feet; **(f)** clinical manifestations of patient No. 8, skin lesions on the feet of an adolescent male child. Color images available online at [www.liebertpub.com/gtmb](www.liebertpub.com/gtmb)](fig-1){#f1}

![Sanger sequencing outcomes of polymerase chain reaction products correspondent to each patient. All the panels are ranged according to the orders of patients listed in [Table 1](#T1){ref-type="table"}. Color images available online at [www.liebertpub.com/gtmb](www.liebertpub.com/gtmb)](fig-2){#f2}

###### 

[Gene Mutations and Patient Information]{.smallcaps}

  *No.*   *Ethnic group*   *Gender*   *Age*   *DSH type*   *Lesion*            *Onset time*   *Mutation location*   *Nucleotide change*      *Protein change*   *Reported or not*   *Mutation type*
  ------- ---------------- ---------- ------- ------------ ------------------- -------------- --------------------- ------------------------ ------------------ ------------------- -----------------
  1       Han              M          8y      Familial     Extremities         3y             Exon 13               c.3233G\>A               p.(Arg1078His)     Novel               Missense
  2       Han              M          8y      Familial     Extremities, face   3y             Exon 13               c.3286C\>T               p.(Arg1096^\*^)    Reported            Nonsense
  3       Han              M          22y     Sporadic     Extremities         3y             Intron 11             c.3019 + 1G\>T           Unknown            Novel               Splice-site
  4       Han              M          7y      Sporadic     Extremities, face   1y             Exon 11               c.2894C\>A               p.(Pro965Gln)      Novel               Missense
  5       Han              M          36y     Familial     Extremities         2y             Exon 2                c.1202_1205del           p.(Asn401fs)       Novel               Frame-shift
  6       Han              F          11y     Sporadic     Extremities         2y             Exon 7                c.2280C\>A               p.(Tyr760^\*^)     Novel               Nonsense
  7       Han              F          34y     Sporadic     Extremities, face   6y             Intron 4              c.1934 + 3A\>G           Unknown            Novel               Splice-site
  8       Han              M          7y      Familial     Extremities         2y             Exon 3                c.1615del                p.(Val539fs)       Reported            Frame-shift
  9       Han              F          12y     Sporadic     Extremities         6y             Exon 9                c.2749A\>G               p.(Arg917Gly)      Novel               Missense
  10      Han              F          10y     Familial     Extremities         10y            Exon 2                c.1371_1372insCCACAGAT   p.(Asp458fs)       Reported            Frame-shift
  11      Han              M          41y     Familial     Extremities, face   2y             Intron 13             c.3315 + 1G\>A           Unknown            Reported            Splice-site
  12      Han              F          63y     Familial     Extremities         3y             Exon 7                c.2433_2434del           p.(Thr811fs)       Reported            Frame-shift
  13      Han              M          16y     Familial     Extremities, knee   1m             Exon 7                c.2310_2311insA          p.(Ala771fs)       Novel               Frame-shift

m, months; y, years.

Discussion {#s006}
==========

ADAR1 consists of six domains including two Z-DNA-binding domains, three dsRNA-binding domains (DRBMs), and one catalytic domain (deaminase) (Herbert and Rich, [@B4]). In this study, we identified eight novel and five previously reported *ADAR1* gene mutations in 13 Chinese patients with DSH. Of the 13 *ADAR1* mutations, 4 locate within the DRBMs while 6 mutations locate within the deaminase.

The two Z-DNA-binding motifs and the three DRBMs enhance the efficiency of RNA editing, but are not essential (Herbert *et al.*, [@B5]). DRBMs and the C-terminal portion of the catalytic domain have been shown to induce mRNA translation independently (Herbert *et al.*, [@B5]). Hence mutations in either the DRBMs or the catalytic domain (Hou *et al.*, [@B6]) are likely to have greater effect than that in the two Z-DNA-binding domains.

Depending on different expression patterns, *ADAR1* encodes two isoforms of proteins due to alternative splicing. The interferon-inducible full-length isoform, ADAR1p150, contains a nuclear export signal at the N-terminal of Zα domain, thus leading to the main distribution of this protein in the cytoplasm (Poulsen *et al.*, [@B14]), although the presence of a nuclear localization signal (NLS) in the DRBMs allows it to undergo nucleocytoplasmic shuttling. The shorter isoform, ADAR1p110, consists of merely four domains including the three DRBMs and the catalytic domain, and it is mostly localized in the nucleus owing to NLS (Desterro *et al.*, [@B2]). It is constitutively expressed and edits dsRNA before nuclear export. It may be more indispensable in maintaining normal life activities (Song *et al.*, [@B17]).

Mammalian ADAR1 is a type of house-keeping protein and is ubiquitously expressed in almost all organs. The requirement of ADAR1 for life was first recognized from the embryonic lethality of *Adar1*^−/−^ mice by embryonic day 12.5 (E12.5). Substantial overproduction of interferon and widespread apoptosis were found in these *ADAR1* knockout mice (Wang *et al.*, [@B19]). Pestal *et al.* ([@B13]) have demonstrated that ADAR1, typically ADAR1p110, functions as a key regulator of multiorgan development and homeostasis.

Furthermore, ADAR1 is also found indispensable in skin. Sharma created an epidermis-specific *ADAR1* knockout mouse model to investigate the potential role of *ADAR1* in skin and the correlation between the gene and the disease. Notably, the mice (ADAR1^−/−^) undergone such treatment displayed a phenotype of skin that grossly included fur loss, poor skin resiliency, skin rash, and bleeding (Sharma *et al.*, [@B16]). Interestingly, mice that are heterozygous for *ADAR1* deletion (*ADAR1*^+/−^) do not manifest any gross abnormality of the skin even in the extremities and face (Wang *et al.*, [@B20]) where typical skin lesions of DSH on human sapiens exist.

Up to now, ∼180 mutations in *ADAR1* have been identified worldwide in patients with DSH, whereas most of the cases were reported in East Asia. Mutations in *ADAR1* contribute to several hereditary diseases, including DSH, Aicardi-Goutières syndrome (AGS), and bilateral striatal necrosis, although the hereditary pattern may be varied. For decades, most people attributed DSH to haploinsufficiency of ADAR1. Few researches on interferon status of DSH have been conducted (Mannion *et al.*, [@B10]).

AGS is one hereditary disease of autosomal recessive pattern caused by *ADAR1* mutations (Rice *et al.*, [@B15]). It is a severe autoimmune disease associated with aberrant interferon response. It has been demonstrated that ADAR1p150 is a unique and specific negative regulator of melanoma differentiation-associated gene 5 (MDA5)---mitochondrial antiviral signaling protein (MAVS) pathway that contributes to AGS (Pestal *et al.*, [@B13]). MDA5 is a member of the DExD/H box RNA helicase family and it plays a crucial role in antiviral immune response, including producing abundant type-1 interferon (Lee *et al.*, [@B7]). Song *et al.* ([@B17]) considered DSH as an autoimmune disease also owing to MDA5--MAVS pathway. Besides, they deemed that ADAR1p150 participated in the pathogenic mechanism of DSH. Whether and how MDA5--MAVS pathway functions in the onset and progression of DSH shall be further investigated.

Except for its role as a negative regulator in MDA5--MAVS pathway, ADAR1 catalyzes adenosine residues to inosine in RNA duplexes, including protein-coding transcripts and numerous noncoding RNAs, including microRNA, siRNA, and lncRNA (Mannion *et al.*, [@B10]). Editing of endogenous RNA duplexes may decrease the risk of inducing aberrant innate immune response cascades. Furthermore, this may expand the transcriptome when A-to-I editing occurs within coding sequences or at splice sites. Unfortunately, binding and editing of ADAR1 are generally randomly (Bazak *et al.*, [@B1]), which may partly account for various phenotypes even in one pedigree.

*ADAR1* is typical house-keeping gene and it interacts with other house-keeping genes or tissue-specific genes to perform normal biologic functions (Liu *et al.*, [@B9]). A hidden crosstalk between *ADAR1* and unknown tissue-specific genes or proteins may consequently lead to DSH. Further investigations may be conducted based on the assumption.

Conclusion {#s007}
==========

In conclusion, we have expanded our knowledge of mutation spectrum in DSH by identifying eight novel ADAR1 mutations. The novel mutations include two frame-shift mutations (c.1202_1205del and c.2311insA), three missense mutations (c.2749A\>G, c.2894C\>A, and c.3233G\>A), one nonsense mutation (c.2280C\>A), and two splice-site mutations (c.1934 + 3A\>G and c.3019 + 1G\>T).

The mechanism of DSH is still mysterious. Involvement of MDA5--MAVS pathway or the interaction between ADAR1 and other tissue-specific genes may account for pathogenic mechanism of DSH. Larger spectrum of ADAR1 mutations will help reveal the essence of the disease and the correlation between phenotypes and genotypes. Further investigations shall be focused on the detailed mechanism and potential signaling pathway.
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